Glaucoma News and Research

Latest Glaucoma News and Research

Statins linked to reduced glaucoma risk

Cholesterol-lowering medications in the statin class could significantly reduce the risk for developing open-angle glaucoma, show data for more than 500,000 older-age US individuals with hyperlipidemia.

2 Oct 2012

Statins may protect against glaucoma

People who take statins to reduce their risk of cardiovascular disease are less likely to be diagnosed with the most common form of glaucoma, according to a nationwide study of more than 300,000 patients.

2 Oct 2012

Amakem commences AMA0076 Phase 2a study in glaucoma and ocular hypertension

Amakem NV, a kinase platform company focusing on ophthalmology, today announces that it has initiated a Phase 2a proof of concept study of its novel Rho Kinase (ROCK) inhibitor, AMA0076, in patients with glaucoma and ocular hypertension.

27 Sep 2012

Cost of glaucoma revealed

The first 6 months after an open-angle glaucoma diagnosis are the most costly within the first 2 years of having the condition, report US researchers.

26 Sep 2012

Universitat de València to use optical technology to prevent myopia

The Universitat de València will use optical technology in order to prevent myopia, which is considered the most common eye disease in the world. Until now, this technology was only used in astronomy to study images of the Universe.

26 Sep 2012

pSivida reports revenues of $699,000 for fourth quarter 2012

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its fourth quarter and fiscal year ended June 30, 2012.

25 Sep 2012

Structure and function combined is best for detecting, discriminating glaucoma

An index that combines structure and function measurements can detect perimetric and preperimetric glaucoma more accurately, and can differentiate early, moderate, and advanced disease more successfully than systems that consider either variable alone, report researchers.

21 Sep 2012

Weill Cornell to purchase innovative equipment to help detect and treat diabetic retinopathy

Weill Cornell Medical College's ophthalmology services for diabetic patients received a boost last month, courtesy of a grant from the New York City Council secured by Councilwoman Jessica Lappin.

21 Sep 2012

Mathematical modeling can help treat several diseases

Mathematical modeling being tested by researchers at the School of Science at Indiana University-Purdue University Indianapolis (IUPUI) and the IU School of Medicine has the potential to impact the knowledge and treatment of several diseases that continue to challenge scientists across the world.

21 Sep 2012

FDA approves Acton’s AEROSPAN sNDA to treat asthma

Acton Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the sNDA (Supplemental New Drug Application) for AEROSPAN (flunisolide HFA, 80 mcg) Inhalation Aerosol, a hydrofluoroalkane (HFA) orally inhaled corticosteroid indicated for the maintenance treatment of asthma as a prophylactic therapy in adult and pediatric patients 6 years of age and older.

21 Sep 2012

Small subset of patients with OAG accounts for large proportion of all glaucoma-related charges

A small subset of patients with open-angle glaucoma (OAG) account for a large proportion of all glaucoma-related charges in the United States, according to new data published by researchers at the University of Michigan Kellogg Eye Center and Washington University, St. Louis.

20 Sep 2012

Multiple interventions improve medication adherence for patients with chronic conditions

Although patients with chronic conditions who do not take medications as prescribed tend to have poorer health outcomes and higher health care costs than those who adhere to medication regimens, a new report sheds light on the potential for multiple interventions to improve medication adherence.

13 Sep 2012

Readily available index provides practical landmarks for glaucoma patients

The mean deviation index, a widely understood metric for summarizing damage to an individuals’ visual field, could help physicians estimate practical landmarks in patients with glaucoma such as fitness to drive, report UK researchers.

12 Sep 2012

Joslin Diabetes Center, Mass. Eye and Ear partner to form clinical and research alliance

Massachusetts Eye and Ear and the Joslin Diabetes Center announced today that they have reached agreement to form a clinical and research alliance, aimed toward providing coordinated high quality care to eye patients throughout greater Boston, especially those with or at-risk for diabetes-related eye disease.

11 Sep 2012

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

A synthetic, anti-inflammatory and anti-allergic family of drugs to combat a variety of illnesses while avoiding detrimental side effects has been developed by a Hebrew University of Jerusalem researcher.

7 Sep 2012

Enrollment complete in ACADIA's pimavanserin Phase III trial for Parkinson's disease psychosis

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the completion of enrollment in its ongoing pivotal Phase III trial with pimavanserin in patients with Parkinson's disease psychosis (PDP).

5 Sep 2012

Scientists identify three new genes associated with Primary Angle Closure Glaucoma

Singapore scientists have identified three new genes associated with Primary Angle Closure Glaucoma (PACG), a leading cause of blindness in Chinese people. PACG affects 15 million people worldwide, 80% of whom live in Asia.

5 Sep 2012

Glaucoma and cell death: an interview with Dr. Vivek Gupta

Glaucoma is normally caused by increased pressure of aqueous humour fluid in the eye. A defining feature of this disease is destruction of a particular type of cells in the retina called retinal ganglion cells and excavation of the optic disc region.

31 Aug 2012

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Merz, Inc. today announced the acquisition of CUVPOSA (glycopyrrolate) oral solution for pediatric chronic severe drooling associated with neurologic conditions such as cerebral palsy.

27 Aug 2012

Encouraging results from Ocular Therapeutix's travoprost Phase II trial on glaucoma

Following encouraging results from Ocular Therapeutix's travoprost punctum plug feasibility study, the company is now entering a pilot Phase II clinical trial to examine a two-month sustained release drug (OTX-TP2) for the treatment of ocular hypertension and glaucoma.

21 Aug 2012

Glaucoma News and Research

Latest Glaucoma News and Research

Statins linked to reduced glaucoma risk

Statins may protect against glaucoma

Amakem commences AMA0076 Phase 2a study in glaucoma and ocular hypertension

Cost of glaucoma revealed

Universitat de València to use optical technology to prevent myopia

pSivida reports revenues of $699,000 for fourth quarter 2012

Structure and function combined is best for detecting, discriminating glaucoma

Weill Cornell to purchase innovative equipment to help detect and treat diabetic retinopathy

Mathematical modeling can help treat several diseases

FDA approves Acton’s AEROSPAN sNDA to treat asthma

Small subset of patients with OAG accounts for large proportion of all glaucoma-related charges

Multiple interventions improve medication adherence for patients with chronic conditions

Readily available index provides practical landmarks for glaucoma patients

Joslin Diabetes Center, Mass. Eye and Ear partner to form clinical and research alliance

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

Enrollment complete in ACADIA's pimavanserin Phase III trial for Parkinson's disease psychosis

Scientists identify three new genes associated with Primary Angle Closure Glaucoma

Glaucoma and cell death: an interview with Dr. Vivek Gupta

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Encouraging results from Ocular Therapeutix's travoprost Phase II trial on glaucoma

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Glaucoma News and Research

Latest Glaucoma News and Research

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Newsletters you may be interested in